Shares of REGENXBIO Inc. (NASDAQ:RGNX) traded down NaN during trading on Wednesday . The stock traded as low as $26.50 and last traded at $0.00. 520,092 shares traded hands during mid-day trading, an increase of Infinity from the average session volume of 0 shares.

Several analysts have commented on the stock. BidaskClub raised shares of REGENXBIO from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Evercore ISI assumed coverage on shares of REGENXBIO in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 target price for the company. Chardan Capital lifted their target price on shares of REGENXBIO from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Bank of America Corporation lifted their target price on shares of REGENXBIO from $29.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, September 21st. Finally, Raymond James Financial, Inc. assumed coverage on shares of REGENXBIO in a research note on Thursday, October 12th. They issued an “outperform” rating and a $39.00 target price for the company. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $40.00.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.34. The firm had revenue of $6.56 million for the quarter. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%.

In other REGENXBIO news, CFO Vittal Vasista sold 3,040 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $21.09, for a total value of $64,113.60. Following the transaction, the chief financial officer now owns 103,118 shares in the company, valued at approximately $2,174,758.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Kenneth T. Mills sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $20.05, for a total transaction of $130,325.00. Following the completion of the transaction, the insider now owns 105,500 shares in the company, valued at approximately $2,115,275. The disclosure for this sale can be found here. In the last quarter, insiders sold 210,040 shares of company stock worth $5,874,639. Company insiders own 17.00% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in RGNX. Swiss National Bank increased its stake in REGENXBIO by 30.7% in the 1st quarter. Swiss National Bank now owns 42,600 shares of the biotechnology company’s stock valued at $822,000 after buying an additional 10,000 shares during the period. Parametric Portfolio Associates LLC increased its stake in REGENXBIO by 169.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 40,928 shares of the biotechnology company’s stock valued at $790,000 after buying an additional 25,729 shares during the period. American International Group Inc. increased its stake in REGENXBIO by 7.1% in the 1st quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock valued at $241,000 after buying an additional 822 shares during the period. Vanguard Group Inc. increased its stake in REGENXBIO by 23.2% in the 1st quarter. Vanguard Group Inc. now owns 981,517 shares of the biotechnology company’s stock valued at $18,942,000 after buying an additional 184,700 shares during the period. Finally, Geode Capital Management LLC increased its stake in REGENXBIO by 3.6% in the 1st quarter. Geode Capital Management LLC now owns 171,346 shares of the biotechnology company’s stock valued at $3,306,000 after buying an additional 5,949 shares during the period. Hedge funds and other institutional investors own 73.41% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “REGENXBIO Inc. (RGNX) Shares Down NaN” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://theolympiareport.com/2017/11/02/regenxbio-inc-rgnx-shares-down-nan.html.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.